Galacto-Oligosaccharide/Polidextrose Enriched Formula Protects against Respiratory Infections in Infants at High Risk of Atopy: A Randomized Clinical Trial

Ranucci, Giusy; Buccigrossi, Vittoria; Borgia, Eleonora; Piacentini, Daniela; Visentin, Federica; Cantarutti, Luigi; Baiardi, Paola; Felisi, Mariagrazia; Spagnuolo, Maria Immacolata; Zanconato, Stefania; Baraldi, Eugenio; Giaquinto, Carlo; Guarino, Alfredo

doi:10.3390/nu10030286

Cited by 47 publications

(58 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a randomized clinical trial, a galacto-oligosaccharide/polidextrose enriched formula protected infants who were born to atopic parents from respiratory infections. It increased the colonization of the protective bacteria including Bifidobacteria and Clostridium cluster I (Ranucci et al, 2018).…”

Section: Regulating Inflammation and Immune-responsementioning

confidence: 99%

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

et al. 2020

View full text Add to dashboard Cite

Emerging findings indicate there is a vital cross-talk between gut microbiota and the lungs, which is known as gut-lung axis. The gut disturbances in lung diseases including allergy, asthma, chronic obstructive pulmonary disease, cystic fibrosis and lung cancer were observed by extensive studies. Investigating how gut microbiota impact other distant organs is of great interest in recent years. Although it has not been fully understood whether the disturbance is the cause or effect of lung diseases, alterations in the gut microbial species and metabolites have been linked to changes in immune responses and inflammation as well as the disease development in the lungs. In this article, we systemically review the role and mechanisms underlying the changes in the constituent of gut microbiota and metabolites in lung diseases. In particular, the roles of gut-lung axis in mediating immune responses and reshaping inflammation are highlighted. Furthermore, we discuss the potential of strategies to manipulate the gut microbiota and metabolites as the therapeutic approach for lung diseases.

show abstract

Section: Regulating Inflammation and Immune-responsementioning

confidence: 99%

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A large study found the galacto-oligosaccharide/polydextrose (GOS/PDX)-formula to have a significant protective effect against respiratory infections in young infants. 72 Yet, another large trial study reported no effect of a GOS-containing infant formula on the rate of infections or allergic diseases in infants, even though a clear prebiotic effect was demonstrated by changes in feacal characteristics. 73 Moreover, a RCT by Niele et al 74 , including 113 preterm infants, found no benefits of short-term prebiotic mixture supplementation of neutral and acidic oligosaccharide on the incidence of infectious and allergic conditions in infants during their first year of life.…”

Section: Therapeutic Interventions Targeting the Lung Microbiomementioning

confidence: 99%

The lung microbiome in neonates

et al. 2019

View full text Add to dashboard Cite

Despite the advent of culture-independent techniques to identify members of the microbiome, studies focusing on the lung microbiome of neonates are scarce. Understanding the role of the microbiome in the pathogenesis of pulmonary conditions affecting newborns could lead to the initiation of pioneering therapeutic interventions, which could potentially prevent lifelong disability. Bronchopulmonary dysplasia (BPD) has been associated with a less diverse microbiome, presence of Ureaplasma species and reduced Lactobacillus detection. Additionally, the potential role of microbial dysbiosis in the pathogenesis of asthma, cystic fibrosis and pneumonia has been described. There has also been a surge of interest in attempting to elucidate the interactions between the airway and gut microbiomes and their bearings on respiratory health and diseases to eventually broaden the scope of therapeutic interventions.

show abstract

“…Several intervention studies have reported the functional benefit of adding prebiotic oligosaccharides to infant formula. More specifically, specific prebiotic oligosaccharides have been shown to ameliorate the development of allergies as well as reduce the impact of pediatric infections ( 4 , 5 , 73 – 75 ). In this regard, the immune modulating effect that seems to decrease the risk on developing atopy and allergy, also may lower the infection risk in neonates, which is suggestive for basic immune modulation early in life.…”

Section: Human Milk Oligosaccharide Impact In Vivomentioning

confidence: 99%

“…Although growth and 2′-FL uptake were similar between formula receiving infants and as seen in breastfed infants, the possible functional benefits regarding immune development and/or infection susceptibility related to a single oligosaccharide are however not extractable from these studies. Therefore, the identification and understanding of protective elements in human breast milk decreasing infant's susceptibility to infection remains limited ( 75 ).…”

Section: Human Milk Oligosaccharide Impact In Vivomentioning

confidence: 99%

Diversity of Human Milk Oligosaccharides and Effects on Early Life Immune Development

et al. 2018

View full text Add to dashboard Cite

One of the well-known features of human milk, is the capacity to protect against the risk and impact of neonatal infections, as well as to influence the onset of allergic and metabolic disease manifestations. The major objective of this review is to provide a detailed overview regarding the role of human milk, more specifically the diversity in human milk oligosaccharides (HMOS), on early life immune development. Novel insights in immune modulatory effects of HMOS obtained by in vitro as well as in vivo studies, adds to the understanding on how early life nutrition may impact immune development. Extensive description and analysis of single HMOS contributing to the diversity within the composition provided during breastfeeding will be discussed with specific emphasis on immune development and the susceptibility to neonatal and childhood infections.

show abstract

Galacto-Oligosaccharide/Polidextrose Enriched Formula Protects against Respiratory Infections in Infants at High Risk of Atopy: A Randomized Clinical Trial

Cited by 47 publications

References 33 publications

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

The lung microbiome in neonates

Diversity of Human Milk Oligosaccharides and Effects on Early Life Immune Development

Contact Info

Product

Resources

About